MapLight Therapeutics, Inc. Common Stock (MPLT)vsRevolution Medicines Inc (RVMD)
MPLT
MapLight Therapeutics, Inc. Common Stock
$28.01
-6.94%
HEALTHCARE · Cap: $1.31B
RVMD
Revolution Medicines Inc
$155.69
+3.31%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
MPLT
Avoid24
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MPLT
The strongest argument for MPLT centers on Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : MPLT
The primary concerns for MPLT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
MPLT is growing revenue faster at 0.0% — sustainability is the question.
MPLT generates stronger free cash flow (-51M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MPLT scores higher overall (24/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MapLight Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
MapLight Therapeutics, Inc. is an innovative biotechnology company dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders. Utilizing its proprietary platform, the firm strategically targets intricate biological pathways, aiming to deliver transformative treatment solutions that significantly enhance patient outcomes. With a robust commitment to scientific excellence and a well-advancing clinical pipeline, MapLight is positioned to address critical unmet medical needs, establishing itself as a potential leader in the dynamic neurotherapeutics market.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?